Adjuvant chemotherapy with S-1 (tegaful, gimeracil and oteracil potassium) is tolerable in Chinese patients with gastric adenocarcinoma, a study in Hong Kong has shown.
The management of osteoporosis calls for a range of strategies, including pharmacotherapy. At a meeting organized by The Osteoporosis Society of Hong Kong, Professor Markus Seibel of the University of Sydney, Australia, reviewed current pharmacological therapies for osteoporosis.
Inhaled corticosteroids (ICS) have been regarded as a cornerstone of chronic obstructive pulmonary disease (COPD) management. However, their role has limitations following reports that long-term use, especially at high doses, is associated with an increased risk of pneumonia. At a Novartis-sponsored symposium during the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) in Bangkok, Thailand, Dr Chin-Kook Rhee of Seoul St Mary’s Hospital, Catholic University of Korea, discussed issues in COPD management specific to the Asia-Pacific region and how treatment goals could be met through dual bronchodilator therapy with a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), such as indacaterol in combination with glycopyrronium (Ultibro®, Novartis).
The use of certain systemic medications may influence intraocular pressure (IOP), and potentially, glaucoma risk, according to a post hoc analysis of the SEED* study.
An upcoming disposable positive expiratory pressure (PEP) device for individuals with cystic fibrosis may lessen the occurrence of infections and subsequently, reduce antibiotic use and medical consultations, said researchers from the University of Limerick, Ireland.